Vyleesi® product results: 14% growth in prescriptions dispensed over prior quarter – 7 consecutive quarters of double digit growth. Click here to learn more ›

Phase IIa Study of the NPR-Agonist, PL-3994, in Healthy Adult Volunteers with Controlled Hypertension

Leave a Reply

Scroll to Top